Health

WOW – Drug Shows 100% Remission For All Cancer

Published on June 7, 2022

Some great news was just published in the New England Journal of Medicine (NEJM).

They announced that a potentially new miracle cancer treatment resulted in remission for every patient enrolled in a clinical trial at the Memorial Sloan Kettering Cancer Center.

Eighteen patients diagnosed with rectal cancer enrolled in that drug trial with GlaxoSmithKline, abstaining from grueling treatments like chemotherapy. Incredibly, all participants saw their tumors disappear, according to the trial results published Sunday in the New England Journal of Medicine (NEJM).

It appears to be the first cancer drug study conducted in which all subjects became fully cancer-free as a result. At the trial’s conclusion, there were no signs of a remaining tumor when the patients were given physical exams, endoscopies, PET scans, and MRIs.

RESULTS

“A total of 12 patients have completed treatment with dostarlimab and have undergone at least 6 months of follow-up. All 12 patients (100%; 95% confidence interval, 74 to 100) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging, ¹⁸F-fluorodeoxyglucose–positron-emission tomography, endoscopic evaluation, digital rectal examination, or biopsy. At the time of this report, no patients had received chemoradiotherapy or undergone surgery, and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months). No adverse events of grade 3 or higher have been reported.”

Very proud of our study published in @NEJM. 100% clinical complete response with dostarlimab alone in mismatch repair-deficient locally advanced #RectalCancer. No radiation or surgery! @ASCO #ASCO22 @MSKCancerCenter https://t.co/sZypoHBtj7

— Andrea Cercek (@AndreaCercek) June 5, 2022

In what would significantly remove any hesitancy, and ensure complete acceptance by those in need of the drugs, none of the patients in the study have reported adverse reactions during the drug trial, which is rare in treatments of its type.

According to The New York Times, about 20% of patients treated with checkpoint inhibitors have some sort of adverse reaction.

“I believe this is the first time this has happened in the history of cancer,” Dr. Luis A. Diaz Jr., who had described the results in the New England Journal of Medicine, told The New York Times.